VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from…
Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022 Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1) administration in frontline Glioblastoma (GBM)…
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study…
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that tumor response and overall survival data…
Updated 12-month and 18-month overall survival data demonstrate continued improvements compared to historical controls1 1 patient remaining on protocol has achieved progression-free survival beyond 86 weeks, demonstrating 93% tumor reduction…

12-month overall survival (OS) : 60% (n=6/10) in VBI-1901 + GM-CSF study arm compared to historical controls of ~30%1 – 12-month OS not yet reached with VBI-1901 + AS01B2 6-month…
